Patent · US Active

Arylquinazolines

US9732094B2 · kind B2 · utility

4Cited by

1References

3Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Thomas Fuchss · Bensheim, DE
Ulrich Emde · Darmstadt, DE
Hans-Peter Buchstaller · Griesheim, DE
Werner Mederski · Zwingenberg, DE

Key dates

Filing date	May 8, 2014
Grant date	Aug 15, 2017
Priority date	—
Expiry date	May 8, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.